PAD4 has previously been shown to be elevated in lung adenocarcinoma, to play roles in A549 EMT transition [85,86] and to be important for PAD4-mediated NETosis in lung epithelial malignancies [87], while PADI2 has been related to prostate cancer proliferation [88] and is elevated in breast cancer [89]. Here, PADI4 is linked to prostate carcinoma.